drugset / Trial / NCT03020810

Dupilumab Compassionate Use Study

NCT03020810

Expanded access Approved for marketing Sally E. Wenzel MD

Summary

This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications